Literature DB >> 24686725

Cognitive-behavioral therapy for medication-resistant psychosis: a meta-analytic review.

Amy M N Burns1, David H Erickson1, Colleen A Brenner1.   

Abstract

Patients with schizophrenia often continue to experience disabling positive symptoms, despite adequate trials of medication. In these situations, patients may be prescribed an adjunctive medication, but a more effective choice may be cognitive-behavioral therapy (CBT). This review of 16 published articles from 12 randomized controlled trials found that CBT was associated with robust improvements in the positive symptoms of psychotic disorders. In addition, the improvements were sustained at follow-up, the authors reported.

Entities:  

Mesh:

Year:  2014        PMID: 24686725     DOI: 10.1176/appi.ps.201300213

Source DB:  PubMed          Journal:  Psychiatr Serv        ISSN: 1075-2730            Impact factor:   3.084


  32 in total

1.  What is the risk-benefit ratio of long-term antipsychotic treatment in people with schizophrenia?

Authors:  Christoph U Correll; Jose M Rubio; John M Kane
Journal:  World Psychiatry       Date:  2018-06       Impact factor: 49.548

2.  Progress in Schizophrenia Research and Treatment.

Authors: 
Journal:  Focus (Am Psychiatr Publ)       Date:  2020-11-05

3.  The promise of cognitive behavior therapy for treatment of severe mental disorders: a review of recent developments.

Authors:  Michael E Thase; David Kingdon; Douglas Turkington
Journal:  World Psychiatry       Date:  2014-10       Impact factor: 49.548

4.  Community Health Workers: a Resource to Support Antipsychotic Medication Adherence.

Authors:  Caitlin G Allen; Michael A Sugarman; Ashley Wennerstrom
Journal:  J Behav Health Serv Res       Date:  2017-04       Impact factor: 1.505

Review 5.  Methamphetamine psychosis: epidemiology and management.

Authors:  Suzette Glasner-Edwards; Larissa J Mooney
Journal:  CNS Drugs       Date:  2014-12       Impact factor: 5.749

Review 6.  Treatment resistant schizophrenia: Clinical, biological, and therapeutic perspectives.

Authors:  Frederick C Nucifora; Edgar Woznica; Brian J Lee; Nicola Cascella; Akira Sawa
Journal:  Neurobiol Dis       Date:  2018-08-29       Impact factor: 5.996

7.  Evaluation of a positive psychotherapy group intervention for people with psychosis: pilot randomised controlled trial.

Authors:  Beate Schrank; Tamsin Brownell; Zivile Jakaite; Charley Larkin; Francesca Pesola; Simon Riches; Andre Tylee; Mike Slade
Journal:  Epidemiol Psychiatr Sci       Date:  2015-02-20       Impact factor: 6.892

Review 8.  Dopaminergic dysfunction and excitatory/inhibitory imbalance in treatment-resistant schizophrenia and novel neuromodulatory treatment.

Authors:  Masataka Wada; Yoshihiro Noda; Yusuke Iwata; Sakiko Tsugawa; Kazunari Yoshida; Hideaki Tani; Yoji Hirano; Shinsuke Koike; Daiki Sasabayashi; Haruyuki Katayama; Eric Plitman; Kazutaka Ohi; Fumihiko Ueno; Fernando Caravaggio; Teruki Koizumi; Philip Gerretsen; Takefumi Suzuki; Hiroyuki Uchida; Daniel J Müller; Masaru Mimura; Gary Remington; Anthony A Grace; Ariel Graff-Guerrero; Shinichiro Nakajima
Journal:  Mol Psychiatry       Date:  2022-04-20       Impact factor: 15.992

9.  Acceptance and Efficacy of Metacognitive Training (MCT) on Positive Symptoms and Delusions in Patients With Schizophrenia: A Meta-analysis Taking Into Account Important Moderators.

Authors:  Carolin Eichner; Fabrice Berna
Journal:  Schizophr Bull       Date:  2016-01-08       Impact factor: 9.306

10.  Targets and outcomes of psychotherapies for mental disorders: an overview.

Authors:  Pim Cuijpers
Journal:  World Psychiatry       Date:  2019-10       Impact factor: 49.548

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.